Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bevacizumab plus modified FOLFIRINOX for mucinous ovarian, fallopian tube, or primary peritoneal carcinoma
KCT0007399Phase 2Recruiting
- Sponsor
- Korean Cancer Study Group
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in mucinous ovarian cancer (MOC), ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Korean Cancer Study Group. Started Oct 2022; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
mucinous ovarian cancer (MOC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on KCT0007399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007399.